Neuraxon, Inc.

Affinium Pharmaceuticals, Inc.

Debiopharm International, S.a.

Avanir Pharmaceuticals

Jailall Ramnauth

Shawn Maddaford

Suman Rakhit

Subhash Annedi

Paul Renton

Joanne Patman

Peter Brent Sampson

Heinz W Pauls

Andras Toro

Peter Dove

Sarah Silverman

Henry Pauls

Matthew Surman

David Douglas Manning

Judd Berman

Helene Decornez

John S Andrews

Jagadish C Sircar

Mark L Richards

Bruce J Sargent

Fernando J Martin

Dejian Xie

Gabriela Mladenova

Namrta Bhardwaj

Svetoslav Bratovanov

Subhash C Annedi

Judd M Berman

Helene Yvonne Decornez

Bruce Jeremy Sargent

Fernando J L Martin

In part, the present invention is directed to antibacterial compounds and salts thereof.

Salts, prodrugs and polymorphs of fab I inhibitors

In part, the present invention is directed to antibacterial compounds.

Acrylamide derivatives as Fab I inhibitors

The invention features methods of treating visceral pain or a condition in a mammal caused by the action of nitric oxide synthase (NOS) or by the action of serotonin 5HT1D/1B receptors, by administering to a patient in need thereof a therapeutically effective amount of an indole compound of Formula (I), or a pharmaceutically acceptable salt or prodrug thereof. The methods of the invention may further comprise the administration of additional therapeutic agent. The invention also features new compounds of Formula (I), pharmaceutical compositions thereof, and methods of resolving enantiomeric mixtures.

Indole compounds and methods for treating visceral pain

The present invention features benzoxazines, benzothiazines, and related compounds that inhibit nitric oxide synthase (NOS), particularly those that selectively inhibit neuronal nitric oxide synthase (nNOS) in preference to other NOS isoforms. Exemplary compounds are of the formula: The NOS inhibitors of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing various medical conditions.

Benzoxazines, benzothiazines, and related compounds having NOS inhibitory activity

The present invention features inhibitors of nitric oxide synthase (NOS), particularly those that selectively inhibit neuronal nitric oxide synthase (nNOS) in preference to other NOS isoforms. The NOS inhibitors of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing conditions such as, for example, stroke, reperfusion injury, neurodegeneration, head trauma, CABG, migraine headache with and without aura, migraine with allodynia, central post-stroke pain (CPSP), neuropathic pain, morphine/opioid induced tolerance and hyperalgesia.

Substituted indole compounds having NOS inhibitory activity

Therapeutic agents, and methods of making and using the same

The present invention features quinolones, tetrahydroquinolines, and related compounds that inhibit nitric oxide synthase (NOS), particularly those that selectively inhibit neuronal nitric oxide synthase (nNOS) in preference to other NOS isoforms. The NOS inhibitors of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing various medical conditions.

Quinolone and tetrahydroquinolone and related compounds having NOS inhibitory activity

The present invention features benzothiazines that inhibit nitric oxide synthase (NOS), particularly those that selectively inhibit neuronal nitric oxide synthase (nNOS) in preference to other NOS isoforms, and that have the formula: The NOS inhibitors of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing various medical conditions.

The present invention features inhibitors of nitric oxide synthase (NOS), particularly those that selectively inhibit neuronal nitric oxide synthase (nNOS) in preference to other NOS isoforms. The NOS inhibitors of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing conditions such as, for example, stroke, reperfusion injury, neurodegeneration, head trauma, CABG, migraine headache with and without aura, migraine with allodynia, central post-stroke pain (CPSP), neuropathic pain, or chronic pain.

1,5 and 3,6-substituted indole compounds having NOS inhibitory activity

In part, the present invention is directed to antibacterial compounds of formula (I) wherein A is a bicyclic heteroaryl ring or a tricyclic ring and Ris an heterocyclic residue; L is a bond, or L is alkyl, alkenyl or cycloalkyl. 

Heterocyclic compounds, methods of making them and their use in therapy

The present invention is directed to small molecule inhibitors of the IgE response to allergens, which are useful in the treatment of allergy and/or asthma or any diseases where IgE is pathogenic. This invention also relates to phenyl-indole molecules that are cellular proliferation inhibitors and thus are useful as anticancer agents. This invention further relates to small molecules which suppress cytokines and leukocytes.

Phenyl-indole compounds for modulating IgE and Inhibiting cellular proliferation

Growing community of inventors

Brampton, Canada

Jailall Ramnauth